Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Cagrilintide

AM-833, Long-acting amylin analogue

Quick Stats
Studies 57
Trials 38
Completed NA INTERVENTIONAL NCT00855439

Evaluation of Exenatide in Patients With Diabetic Neuropathy

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

This study will look at whether or not the medication exenatide improves signs and symptoms of diabetic peripheral neuropathy in people with type 2 diabetes and mild to moderate diabetic peripheral neuropathy.

Detailed Description

This study will look at the effects of the medication exenatide on peripheral neuropathy in people with type 2 diabetes. Exenatide (trade name, BYETTA®) is an injectable medication used by people with type 2 diabetes to control blood sugar. Peripheral neuropathy is a complication of diabetes that can cause symptoms such as numbness, tingling or burning sensations in the feet and hands. Controlling blood sugars levels in type 2 diabetes is thought to prevent, delay or improve the damage to the nerve fibers that causes peripheral neuropathy. There is also some evidence that exenatide may have additional beneficial effects on the peripheral nerves, beyond the benefits of blood sugar control alone. In this study, about half of the participants will take exenatide by injection twice daily and the other half will take insulin glargine (Lantus®) by injection once daily. Both groups are expected to have similar improvement in blood sugar control. This study will show whether exenatide has beneficial effects on neuropathy beyond the benefits of better blood sugar control alone.

Interventions

Name: Exenatide
Type: DRUG
Description: Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels
Name: Glargine
Type: DRUG
Description: Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control

Primary Outcomes

Measure: Confirmed Clinical Neuropathy (CCN)
TimeFrame: 18 Months
Description: CCN was defined by a composite score comprised of at least two positive responses among symptoms, sensory signs, or absent or hypoactive reflexes consistent with a distal symmetrical polyneuropathy (16), and at least one abnormal nerve conduction study result in two anatomically distinct nerves, e.g. the sural sensory and peroneal motor nerves (defined as a amplitude \< 5 μV and a conduction velocity \< 40 m/sec for the sural nerve and an amplitude \< 2.5 μV and a conduction velocity \< 40 m/sec for the peroneal nerve).

Trial Information

NCT ID

NCT00855439

Status

Completed

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

University of Michigan

Last Updated

December 15, 2025